Sunesis Pharmaceuticals, Inc. Announces MD Anderson Sponsored Study Of Vosaroxin In AML And High-Risk MDS Poster To Be Presented At American Society of Clinical Oncology 2014

SOUTH SAN FRANCISCO, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored study of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the 2014 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago, Illinois.

Help employers find you! Check out all the jobs and post your resume.